Steglujan FDA Approval History
Steglujan (ertugliflozin and sitagliptin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor, and dipeptidyl peptidase-4 (DPP-4) inhibitor combination used to improve glycemic control in adults with type 2 diabetes.
Development timeline for Steglujan
|Dec 22, 2017||Approval FDA Approves Steglujan (ertugliflozin and sitagliptin) for Type 2 Diabetes|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.